David C. Fisher

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma

Christopher J. Gibson, R. Coleman Lindsley, Vatche Tchekmedyian et al. · Journal of Clinical Oncology · 2017 · 470 citations · Full text

Medicine, Hematology, Oncology +17

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma

Hayley J. Sharpe, Grégoire Pau, Gerrit J.P. Dijkgraaf et al. · Cancer Cell · 2015 · 389 citations · Full text

Medicine, Genetics, Molecular Genetics +15

Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

Rachael A. Clark, Rei Watanabe, Jessica E. Teague et al. · Science Translational Medicine · 2012 · 367 citations

Life Sciences, Immunology, Oncology +16